Xspray – Successful submission of IND application to FDA

Booking.com

STOCKHOLM – October 4, 2019. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces that FDA has accepted the company’s submission of IND application for HyNap-Dasa.
Xspray Pharma announces a successful submission of its Investigational New Drug (IND) application to the Food and Drug Administration (FDA), with acceptance date September 30th 2019, in order to obtain permission to produce material for and perform clinical studies with the product candidate HyNap-Dasa.The Division of Hematology Products issued an IND Acknowledgment letter indicating that the application will be

Source: Xspray – Successful submission of IND application to FDA

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.